Thrivent Financial for Lutherans Has $47.03 Million Position in Twist Bioscience Corporation $TWST

Thrivent Financial for Lutherans cut its position in Twist Bioscience Corporation (NASDAQ:TWST) by 15.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,278,359 shares of the company’s stock after selling 230,778 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Twist Bioscience were worth $47,031,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TWST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. Strs Ohio acquired a new position in shares of Twist Bioscience in the 1st quarter valued at approximately $711,000. Hsbc Holdings PLC bought a new stake in Twist Bioscience during the 1st quarter worth approximately $228,000. Jacobs Levy Equity Management Inc. bought a new stake in Twist Bioscience during the 1st quarter worth approximately $1,662,000. Finally, Conestoga Capital Advisors LLC acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $1,044,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TWST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 8th. Barclays increased their target price on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target on the stock. Finally, Evercore ISI reduced their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $44.88.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 31,379 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $986,555.76. Following the sale, the chief executive officer owned 738,809 shares in the company, valued at $23,228,154.96. This represents a 4.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Dennis Cho sold 6,515 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $204,831.60. Following the completion of the transaction, the insider directly owned 121,713 shares of the company’s stock, valued at $3,826,656.72. This represents a 5.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 119,110 shares of company stock worth $3,783,237 over the last 90 days. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Trading Up 0.5%

Shares of NASDAQ:TWST opened at $31.07 on Tuesday. The company’s 50-day moving average price is $30.91 and its two-hundred day moving average price is $31.12. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $55.33. The stock has a market capitalization of $1.90 billion, a PE ratio of -23.72 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. On average, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.